Clinical Trial Update: BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 clinical trial evaluating BB-10901 in patients with relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BB-10901

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED